Videos

Jamie Koprivnikar, MD, discusses factors that signal a need to transition a patient with lower-risk MDS from an ESA to another therapy.

Highlighting recent data from a post hoc analysis from the COMMANDS trial, a hematologist-oncologist offers insights on important factors to consider when assessing quality of life in patients with MDS.

Jamie Koprivnikar, MD, discusses how findings from the COMMANDS trial can be used to inform treatment decisions for patients based on serum EPO levels and the presence or absence of ring sideroblasts.

Focusing on molecular prognostic models in LR-MDS, Jamie Koprivnikar, MD, shares insights gleaned from the COMMANDS trial on how mutational burden impacts response.

A hematologist-oncologist provides expert perspectives on the development and implementation of the IPSS-M as a clinical-molecular prognostic model in lower-risk MDS.

Jamie L. Koprivnikar, MD, presents a case of a 70-year-old man with SF3B1+ MDS with ring sideroblasts and discusses the approach to initial therapy in patients with lower-risk MDS who may have moderate-to-severe anemia.

Kenneth Shain, MD, PhD, discusses the rationale for giving chimeric antigen receptor (CAR) T-cell therapy in earlier lines of therapy for relapsed/refractory (R/R) multiple myeloma.

Jeff Sharman, MD, discusses findings from the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for the treatment of patients with treatment-naive chronic lymphocytic leukemia.

Solly Chedid, MD, shares insights on optimizing anemia management in patients with lower-risk MDS and outlines remaining unmet needs in treating anemia.

An expert on myelodysplastic syndromes reviews recent real-world data presented at EHA 2024 showing the clinical benefit of luspatercept dose titration.

Solly Chedid, MD, provides clinical insights on quality-of-life assessment practices for patients with MDS.

A hematologist-oncologist discusses the efficacy and safety findings from the COMMANDS trial and how they inform treatment selection.

Solly Chedid, MD, presents a patient case and provides clinical insights on approaching first-line therapy selection in patients with LR-MDS and moderate to severe anemia.

Mikkael A. Sekeres MD, MS, discusses transfusion independence rates with imetelstat in patients with low- to intermediate-1 risk myelodysplastic syndromes.

Anil Parwani, MD, PhD, professor of pathology at The Ohio State University Wexner Medical Center, discusses the artificial intelligence (AI) technology that is currently being used at his institution.

Aakash Desai, MD, MPH, discusses the ADRIATIC study in limited-stage small cell lung cancer.

Sangeetha Venugopal, MD, MS, discusses what she is most interested about regarding unmet needs in patients with AML.

In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discusses real-world findings of brexucabtagene autoleucel in relapsed/refractory B-cell ALL.

Sangeetha Venugopal, MD, MS, discusses the evolving field of acute myeloid leukemia treatment.

Claire Saxton, MBA, discusses a study on the concept of social toxicity in patients with acute myeloid leukemia.

Ira Zackon, MD, discusses what strategies community oncology practices can implement to address racial and socioeconomic disparities in chronic lymphocytic leukemia.

Nazli Dizman, MD, discusses the current accountability measures for enforcing the language of respect guidelines in renal cell carcinoma.

Key opinion leaders present an overview of first-line immune checkpoint inhibitor combination regimens specifically tailored for patients with favorable-risk metastatic renal cell carcinoma.

Medical experts examine the case of a 61-year-old male patient with a history of low-volume, indolent metastatic clear cell renal cell carcinoma, who has undergone left nephrectomy and adrenalectomy.

Adrienne Waks, MD, discusses the unmet needs in early-stage HER2-positive breast cancer.

Jeff Sharman, MD, discusses the background of the ELEVATE-TN trial and its long-term efficacy data.

Medical experts explore how improved hemoglobin levels with luspatercept treatment impact overall well-being and daily functioning, with insights from the post-hoc analysis of the COMMANDS study revealing relationships between hemoglobin levels and quality of life.

Medical experts examine the role of luspatercept as a first-line treatment for anemia in lower-risk MDS patients, including those with RS+/RS- and serum EPO ≤200 mU/L, and discuss its efficacy and potential benefits for this population.

Yeon Hee Park, MD, discusses the unmet needs in among premenopausal patients with metastatic breast cancer.